Search clinical trials for: Efmoroctocog Alfa Injection [Eloctate]

Total 121 results

Swedish Orphan Biovitrum

Active, not recruiting

A 48-Month Study to Evaluate Long-Term Effectiveness of Elocta on Joint Health (A-MORE)

Hemophilia A

Spain, Germany, Czechia, Italy, Estonia, Finland, Greece, Netherlands, Saudi Arabia, Slovenia, Sweden, Switzerland, United Kingdom
Swedish Orphan Biovitrum

Completed

A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B (PREVENT)

Haemophilia A | Haemophilia B

Germany
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

A Study to Evaluate Efficacy of rFVIIIFc for Immune Tolerance Induction (ITI) in Severe Hemophilia A Participants With Inhibitors Undergoing the First ITI Treatment (verITI-8 Study)

Hemophilia A With Inhibitors

United States, Spain, Canada, Belgium, France, Bulgaria, Italy, United Kingdom, Japan, Germany
The League of Clinical Research, Russia

Completed

Health Related Quality of Life of Youth and Young Adults With Haemophilia A (RELOQ)

Hemophilia A

Russian Federation
Swedish Orphan Biovitrum
ICON plc

Completed

Prospective, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products

Hemophilia A

France, Italy, Norway, Sweden, United Kingdom, Austria, Belgium, Finland, Spain
Bioverativ Therapeutics Inc.

Completed

Pharmacokinetics of rFVIIIFc at Two Vial Strengths

Severe Hemophilia A

United States, United Kingdom, Australia
Bioverativ, a Sanofi company
Swedish Orphan Biovitrum

Completed

An Open Label Study to Determine the Safety and Efficacy of Replacement Factor VIII Protein (Known as rFVIIIFc) in Previously Untreated Males With Severe Hemophilia A

Hemophilia A

United States, France, Italy, Spain, Netherlands, United Kingdom, Ireland, New Zealand, Poland, Australia, Germany, Brazil, Sweden, Canada
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Pharmacokinetics and Safety of rFVIIIFc Manufactured at 15,000 L (15K) Scale (Elevate)

Severe Hemophilia A

United States, Australia, New Zealand
Bioverativ Therapeutics Inc.

Completed

Long-Term Safety and Efficacy of rFVIIIFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia A (ASPIRE)

Hemophilia A

United States, Canada, Italy, Australia, Austria, Belgium, Brazil, France, Germany, Hong Kong, India, Ireland, Israel, Japan, Netherlands, New Zealand, Poland, South Africa, Spain, Sweden, Switzerland, United Kingdom
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Completed

Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Recombinant Coagulation Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Pediatric Subjects With Hemophilia A (Kids ALONG)

Hemophilia A

United States, Poland, United Kingdom, Netherlands, South Africa, Hong Kong, Australia, Ireland
Wyeth is now a wholly owned subsidiary of Pfizer

Terminated

Study Evaluating The Efficacy And Safety Of Xyntha In Children Less Than 6 Years Of Age

Hemophilia A
Pfizer

Completed

Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Hemophilia A

United States, Argentina, Austria, Colombia, Croatia, Jordan, Mexico, New Zealand, Oman, Peru, Poland, Romania, Turkey
Pfizer

Completed

Moroctocog Alfa (AF-CC) for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Hemophilia A Patients

Hemophilia A

India
Pfizer

Completed

Study Evaluating Pharmacovigilance Of Refacto AF

Hemophilia A

Germany, Austria
Pfizer

Completed

Relative Bioavailability Of Two Formulations Of Moroctocog Alfa (AF-CC)

Hemophilia A

United Kingdom, Hungary, Bulgaria
Pfizer

Withdrawn

Patient-reported Outcomes in Subjects Treated With ReFacto AF Routine Prophylaxis

Hemophilia A
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating Refacto For Pharmacovigilance

Hemophilia A

Germany, Austria
University of New Mexico
University of Colorado, Denver; Thrasher Research Fund; Intermountain Health...

Completed

Darbepoetin Administration to Preterm Infants

Infant, Newborn

United States
Pfizer

Completed

Post Marketing Surveillance To Observe Safety And Efficacy Of Xyntha® In Subjects With Hemophilia A

Hemophilia A

Korea, Republic of
Pfizer

Terminated

Study Evaluating Safety Of Patients Switching To ReFacto AF In Usual Care Settings

Hemophilia A

Netherlands, Spain, Greece, Italy, France, Belgium, Germany, Austria, Sweden, Hungary, Finland, United Kingdom, Denmark, Romania
Bioverativ Therapeutics Inc.
Swedish Orphan Biovitrum

Terminated

Fc factOrs and Real-World hemophiliA Patient-ReporteD Outcomes (FORWARD)

Hemophilia A | Hemophilia B

United States
Pfizer

Completed

Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients

Hemophilia A

Spain, Finland, Serbia, Georgia, Italy, Romania, Sweden, Turkey, Ukraine
Hallym University Medical Center

Recruiting

High Dose IV Iron Plus ESA in Chemotherapy-induced Anemia

Anemia

Korea, Republic of
Pfizer

Completed

PF-05208756, Moroctocog Alfa (AF-CC), Xyntha For Hemophilia A

Hemophilia A

China
Pfizer

Terminated

Study Evaluating The Safety Of Xyntha In Usual Care Settings

Hemophilia A

United States, New Zealand
Henrik Wiggers

Recruiting

Physiological Effects of Lactate in Individuals With Chronic Heart Failure

Heart Failure, Systolic

Denmark
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals

Recruiting

Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA

Myelodysplastic Syndromes

United States
Genzyme, a Sanofi Company

Completed

A New Study to Follow-up Thyroid Cancer Patients Who Participated in a Previous Study, Which Compared the Success of Destruction of the Thyroid Remnant Using Standard Treatment or Thyrogen.

Differentiated Thyroid Cancer

United States, France, Canada, Germany, Italy
Angde Biotech Pharmaceutical Co., Ltd.

Recruiting

A Study of PEG-EPO Injection (CHO Cells) for Maintenance Therapy of Patients With Renal Anemia .

Renal Anemia

China
Peking Union Medical College Hospital

Unknown

Using Sodium Lactate Ringer's Injection Resuscitate Septic Shock Patients

Lactate | Severe Sepsis With Septic Shock
Centre Hospitalier Universitaire de Nīmes

Completed

Early Administration of Recombinant Erythropoietin (RHEPO) in Transfusion Savings in Trauma Patients (EPREX)

Trauma

France
Instituto Bernabeu

Recruiting

Continuous Double Ovarian Stimulation.

Fertility Issues

Spain
Guangzhou 8th People's Hospital

Recruiting

Functional Cure of Hepatitis B in HIV/HBV Co-infected Patients

Hepatitis B | AIDS

China
University of Texas Southwestern Medical Center

Recruiting

POCUS: Hemostatic Potential and Joint Health in Patients With Severe Hemophilia A on Novel Replacement Therapies

Hemophilia A | Factor VIII

United States
Seoul National University Hospital

Withdrawn

Effect of Erythropoietin in Refractory Autoimmune Encephalitis Patients

Autoimmune Encephalitis

Korea, Republic of
Margaret Ragni
Health Resources and Services Administration (HRSA)

Terminated

The Hemophilia Inhibitor Prevention Trial

Hemophilia A Without Inhibitor

United States
Alexandria University

Completed

Systemic Erythropoietin Injection in Patients Having Optic Atrophy

Optic Atrophy

Egypt
ONL Therapeutics

Completed

ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy Associated With Age-related Macular Degeneration

Geographic Atrophy

New Zealand, Australia
West China Hospital

Not yet recruiting

Accelerated Recovery for Total Knee Replacement Surgery With Preoperative Intravenous Iron Combined With Human Erythropoietin for Rapid Hematopoietic Mobilization to Prevent Postoperative Anemia (Hematoboost)

Total Knee Arthroplasty

China
Jinling Hospital, China
Ministry of Health, China

Completed

Oxidative Stress and Inflammation Caused by Intravenous Iron in Crohn's Disease Patients With Iron Deficiency Anemia (CD-AT1)

Crohn's Disease

China
Johns Hopkins University
Eiger BioPharmaceuticals

Terminated

Peginterferon Lambda-1a for the Prevention and Treatment of SARS-CoV-2 (COVID-19) Infection (PROTECT)

Sars-CoV-2 Infection

United States
Groupe Francophone des Myelodysplasies
Celgene

Recruiting

Study Evaluating Combination of Luspatercept in LR-MDS Without RS Having Failed or Being Ineligible to ESA

Myelodysplastic Syndromes | MDS

France
Peking University Third Hospital

Recruiting

Sequential Therapy of TCM Herbs to Improve the Success Rate of IVF-ET in Diminished Ovarian Reserve Patients

Infertility, Female

China
Qing XIe

Recruiting

A Prospective Study to Evaluate Peginterferon in Reducing the Incidence of HCC in CHB Patients

Chronic Hepatitis B | Intermediate to High Risk of HCC

China
Shenyang Sunshine Pharmaceutical Co., LTD.

Unknown

rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics

Chronic Renal Failure

China
Shenzhen Second People's Hospital

Recruiting

Roxadustat for Anemia in Patients With CKD

Anemia of Chronic Kidney Disease

China
Xiamen Amoytop Biotech Co., Ltd.
Peking University First Hospital

Completed

A Study of Peginterferon Alfa-2b Combined With TDF in Patients With Chronic Hepatitis B

Chronic Hepatitis B

China
Ain Shams University
National Institute of Urology and Nephrology

Completed

Efficacy Study of Zinc Supplementation on Anemia, Oxidative Stress and Inflammation in Hemodialysis Patients

End Stage Renal Disease

Egypt
Institute of Liver and Biliary Sciences, India

Completed

Randomized Controlled Trial to Study the Outcome of Intravenous Phosphate Supplementation in Live Donors Undergoing Hepatectomy for Living Donor Liver Transplantation (LDLT)

Complication, Postoperative | Regeneration Liver

India
Megalabs

Not yet recruiting

Biosimilarity Study of Subcutaneous Recombinant Human Erythropoietin in Healthy Volunteers

Healthy

Search clinical trials for: Efmoroctocog Alfa Injection [Eloctate]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Türkiye

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations